| Clinical data | |
|---|---|
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 911207-68-6 |
| ATC code | ? |
| PubChem | CID 10086063 |
| Chemical data | |
| Formula | C19H26N2O |
| Mol. mass | 298.205 g/mol |
| SMILES | eMolecules & PubChem |
| |
|
8-Carboxamidocyclazocine (8-CAC) is an opioid analgesic drug related to cyclazocine, invented by the chemist Mark P. Wentland and co-workers. Similarly to cyclazocine, 8-CAC acts as an agonist at both the μ and κ opioid receptors, but has a much longer duration of action than cyclazocine, and does not have μ antagonist activity. Unexpectedly it was discovered that the phenolic hydroxyl group of cyclazocine could be replaced by a carboxamido group with only slight loss of potency at opioid receptors, and this discovery has subsequently been used to develop a large number of novel opioid derivatives where the phenolic hydroxy group has been replaced by either carboxamide or a variety of larger groups. Due to their strong κ-opioid agonist activity, these drugs are not suited for use as analgesics in humans, but have instead been researched as potential drugs for the treatment of cocaine addiction.[1][2][3][4][5][6][7][8][9]
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)